Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company’s stock to newly hired employees on June 10, 2025 in connection with the commencement of employment. The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics presents data at EASL Congress 2025
- Aligos Therapeutics Reports Strong Q1 2025 Progress
- Aligos Therapeutics reports Q1 EPS ($2.11), consensus ($3.15)